RT Journal Article
SR Electronic
T1 Feasibility of Reductive Hepatectomy in Patients With BCLC B and C Hepatocellular Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1975
OP 1983
DO 10.21873/anticanres.14965
VO 41
IS 4
A1 YASUHARA, YUKI
A1 KOMATSU, SHOHEI
A1 KURAMITSU, KAORI
A1 KIDO, MASAHIRO
A1 TANAKA, MOTOFUMI
A1 GON, HIDETOSHI
A1 YANAGIMOTO, HIROAKI
A1 TOYAMA, HIROCHIKA
A1 AJIKI, TETSUO
A1 FUKUMOTO, TAKUMI
YR 2021
UL http://ar.iiarjournals.org/content/41/4/1975.abstract
AB Background/Aim: Few studies have established a definite conclusion regarding the limitation of surgical treatment for patients with Barcelona Clinic Liver Cancer (BCLC) stage B and C hepatocellular carcinoma (HCC). Patients and Methods: A retrospective analysis was performed on 717 consecutive patients who underwent initial hepatectomy for HCC. Results: Reductive hepatectomy was performed in 103 patients, with a median survival time (MST) of 18.0 months. Total bilirubin and albumin levels were identified as independent prognostic factors. The predictive score of these factors ranged from 0 to 2. Subsequent local treatment was performed in 91.0, 75.0, and 25.0% of patients who scored 0, 1, and 2, respectively. The MST for patients with a score of 0, 1, and 2 was 20.1, 14.8, and 2.7 months, respectively, with a significant difference. Conclusion: Patients with BCLC stage B and C could be properly treated with reductive hepatectomy and subsequent local treatments.